Berta Torres
A5061281956- HIV/AIDS Research and Interventions
- HIV Research and Treatment
- HIV/AIDS drug development and treatment
- HIV-related health complications and treatments
- COVID-19 Clinical Research Studies
- Long-Term Effects of COVID-19
- SARS-CoV-2 and COVID-19 Research
- HIV, Drug Use, Sexual Risk
- Hepatitis C virus research
- COVID-19 Impact on Reproduction
- Sepsis Diagnosis and Treatment
- Sex work and related issues
- Pneumocystis jirovecii pneumonia detection and treatment
- Liver Disease Diagnosis and Treatment
- Multiple Sclerosis Research Studies
- Lipoproteins and Cardiovascular Health
- Tracheal and airway disorders
- Antibiotic Use and Resistance
- COVID-19 and healthcare impacts
- Hepatitis B Virus Studies
- Immune Cell Function and Interaction
- Epilepsy research and treatment
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Infectious Diseases and Tuberculosis
- Genomics and Rare Diseases
Universitat de Barcelona
2014-2024
Hospital Clínic de Barcelona
2014-2024
Consorci Institut D'Investigacions Biomediques August Pi I Sunyer
2013-2024
Fundació Clínic per a la Recerca Biomèdica
2019-2024
Fundació de Recerca Clínic Barcelona-Institut d’Investigacions Biomèdiques August Pi i Sunyer
2023-2024
Centro de Investigación Biomédica en Red
2022-2024
University of Wisconsin–Madison
2013-2024
Hospital Universitario Miguel Servet
2009-2023
Instituto de Salud Carlos III
2022-2023
Vall d'Hebron Institut de Recerca
2022
The purpose of this study was to evaluate the prevalence sarcopenia in a cohort healthy community-dwelling elderly an urban area Barcelona (Spain) for native benchmarks and compare them with those published other geographical areas.
Background: It is unclear how characteristics, risk factors, and incidence of coronavirus disease 2019 (COVID-19) in people living with HIV (PLWH) differ from the general population. Methods: Prospective observational single-center cohort study adult PLWH reporting symptoms COVID-19. We assessed clinical factors for COVID-19 diagnosis severity, standardized rate ratio cases Barcelona. Results: From 1 March 2020 to 10 May 2020, 53 out 5683 (0.9% confidence interval 0.7–1.2%) were diagnosed...
BackgroundFactors affecting outcomes of SARS-CoV-2 infection in people living with HIV are unclear. We assessed the factors associated diagnosis and severe among HIV.MethodsWe did a retrospective cohort study using data from PISCIS Catalonia (Spain) between March 1 Dec 15, 2020. linked integrated health-care, clinical, surveillance registries through Public Data Analysis for Health Research Innovation Program (PADRIS) to obtain on diagnosis, chronic comorbidities, as well clinical mortality...
BackgroundCalcium is an essential ion for pathogen survival and virulence involved in the regulation of inflammatory response. Hypocalcemia a common laboratory finding critically ill patients. Data regarding levels calcium SARS-CoV-2 infection scarce. Patients with who present hypocalcemia could have worse outcome.MethodsWe performed retrospective analysis hospitalized patients included all had any serum measurement first 72 h since hospital admission. The main objective was to investigate...
The use of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) is mainly based on robust, pivotal clinical trials.To provide data BIC/FTC/TAF in real life.This was an observational, retrospective and single-centre study. We included all adult, treatment-naive (TN) treatment-experienced (TE) people living with HIV (PLWH) starting from 8 June 2018. evaluated effectiveness [on treatment (OT), modified intention-to-treat (mITT) (ITT)], tolerability safety those patients who reached 6...
Abstract Background The use of remdesivir has demonstrated a significant reduction in the time to recovery patients with COVID-19. However, impact on mortality is still controversial. Therefore, it necessary evaluate whether there specific subgroup whom an active antiviral therapy also reduces mortality. Methods Patients admitted for >48 h our hospital SARS-CoV-2 confirmed or suspected infection from February 2020 2021 were retrospectively analysed. primary outcome study was at 30...
Abstract Objectives The safety, immunogenicity, impact on the latent reservoir and rebound of viral load after therapeutic HIV-1 vaccination with recombinant modified vaccinia Ankara-based (MVA-B) vaccine expressing monomeric gp120 fused Gag-Pol-Nef polyprotein clade B or without a drug to reactivate (disulfiram) were assessed. Methods HIV-1-infected patients randomized receive three injections MVA-B (n = 20) placebo 10). Twelve (eight who received four given placebo) fourth dose followed by...
No controlled comparisons between dolutegravir/lamivudine or dolutegravir maintenance therapy have been done. We hypothesized that these options would similar efficacy to triple ART. used an open-label non-inferiority randomized trial comprising two phases: phase A was established test experimental arms did not unacceptable (≥5%) failure rate; B intended include the full number of patients followed for 48 weeks. Treated HIV-1-infected adults with viral load <50 copies/mL ≥12 months, no prior...
Abstract Hospitalized patients with coronavirus disease 2019 (COVID-19) experiencing respiratory symptoms have different complications (inflammatory, co-infection, and thrombotic) that are identifiable by analytics patterns. Personalized treatment decisions decreased early mortality (odds ratio [OR] .144; 95% confidence interval [CI] .03–.686; P = .015). Increasing age (OR 1.06; .038) therapeutic effort limitation 9.684; &lt; .001) were associated higher mortality.
Blocking the PD-1/PD-L1 pathway has emerged as a potential therapy to restore impaired immune responses in human immunodeficiency virus (HIV)-infected individuals. Most reports have studied impact of PD-L1 blockade on effector cells and neglected possible effects regulatory T (Treg cells), which play an essential role balancing immunopathology antiviral responses. The aim this study was define consequences ex vivo Treg from HIV-infected We observed that HIV infection led increase PD-1+...
We reviewed the 24 week outcomes of HIV-infected patients from our hospital who had their ART switched to dolutegravir monotherapy on an individual clinical basis.Retrospective database assessment virally suppressed in whom treating physician 50 mg once daily due one or more following reasons: antiretroviral-related adverse effects; comorbidities; risk interactions; archived resistance. Patients ≥24 weeks follow-up. Population, virological and immunological responses safety tolerability are...
Both immediate and deferred switching from a ritonavir-boosted protease inhibitor (PI/r)-based regimen to dolutegravir (DTG)-based may improve lipid profile. European Network for AIDS Treatment 022 Study (NEAT022) is European, open-label, randomized trial. Human immunodeficiency virus (HIV)-infected adults aged ≥50 years or with Framingham score ≥10% were eligible if HIV RNA was <50 copies/mL. Patients switch PI/r DTG immediately (DTG-I) at week 48 (DTG-D). Week 96 endpoints proportion of...
Abstract Background In some patients the immune response triggered by SARS-CoV-2 is unbalanced, presenting an acute respiratory distress syndrome which in many cases requires intensive care unit (ICU) admission. The limitation of ICU beds has been one major burdens management worldwide; therefore, clinical strategies to avoid admission are needed. Objective We aimed describe influence tocilizumab on need transfer or death non-critically ill patients. Methods A retrospective study 171 with...
<h3>Objective</h3> To understand COVID-19 characteristics in people with multiple sclerosis (MS) and identify high-risk individuals due to their immunocompromised state resulting from the use of disease-modifying treatments. <h3>Methods</h3> Retrospective multicenter registry patients MS suspected or confirmed diagnosis available disease course (mild = ambulatory; severe hospitalization; critical intensive care unit/death). Cases were analyzed for associations between identifying risk...
Journal Article Cohort Profile: PISCIS, a population-based cohort of people living with HIV in Catalonia and Balearic Islands Get access Andreu Bruguera, Bruguera Centre Epidemiological Studies STI HIV/AIDS (CEEISCAT), Department Health, Generalitat de Catalunya, Badalona, SpainInstitute for Health Science Research Germans Trias i Pujol (IGTP), SpainCIBER Epidemiologia y Salud Pública (CIBERESP), Madrid, Spain https://orcid.org/0000-0002-7524-0768 Search other works by this author on: Oxford...
The reduction of risk non-AIDS events after combined antiretroviral therapy (cART) initiation and the crude incidence rate (CIR) these in patients who control viral load without cART (controllers) a cohort 574 antiretroviral-naive with baseline CD4 T cell count above 500 cells/mm³ were assessed. Non-AIDS severe defined as first admission to hospital due non-AIDS-defining malignancies, cardiovascular, neuropsychiatric, liver-related, or end-stage renal disease events. Potential determinants...
Objectives. In some patients the immune response triggered by SARS-CoV-2 is unbalanced, presenting an acute respiratory distress syndrome which in many cases requires intensive care unit (ICU) admission. The limitation of ICU beds has been one major burdens management around world; therefore, clinical strategies to avoid admission are needed. We aimed describe influence tocilizumab on need transfer or death non-critically ill patients. Material and methods. A retrospective study 171 with...
A proportion of patients who spontaneously control viral load (controllers) experienced clinical progression. We hypothesized that microbial translocation would independently determine the rate disease progression in controllers.sCD14, lipopolysaccharide-binding protein (LBP) and EndoCab levels were assessed 114 antiretroviral-naive with CD4(+) T cells above 500 cells/μl (including 63 controllers 51 noncontrollers). The independent predictive value these markers on time to combined endpoint...
Reports on the impact of some antiretrovirals against SARS-CoV-2 infection and disease severity are conflicting.We evaluated effect tenofovir as either alafenamide/emtricitabine (TAF/FTC) or disoproxil fumarate/emtricitabine (TDF/FTC) associated clinical outcomes among people living with HIV (PLWH).We conducted a propensity score-matched analysis in prospective PISCIS cohort PLWH (n = 14 978) Catalonia, Spain. We used adjusted Cox regression models to assess association between...
To evaluate the influence on mortality of empirical double-active combination antimicrobial therapy (DACT) compared with active monotherapy (AM) in septic shock patients. A retrospective study was performed monomicrobial patients admitted to a university centre during 2010–15. propensity score (PS) calculated using logistic regression model taking assigned as dependent variable, and used covariate multivariate analysis predicting 7, 15 30 day for matching who received DACT or AM....